artios header image

News & Events

Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

23 October 2023 | Press release

featured-lg

Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

5 October 2023 | Press release

Article-2-400×400

Professor Sir Stephen Jackson receives a knighthood for services to innovation and research

19 June 2023 | Announcement

Article-5-400×400

IUCT-Oncopole & Artios join forces to overcome resistance to therapies for familial breast cancer

13 April 2023 | Press release

Capture

Genomic Instability and DNA Repair Conference – Keystone Symposia

23 March 2023 | Conferences

featured

EACR-AACR Immune Response and DNA Repair Cancer Fields Converging Conference

23 March 2023 | Conferences

artios header image

Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer

9 February 2023 | Press release

Article-1-1-400×400

Scientists uncover novel DNA repair mechanism for key cancer target

7 December 2022 | Media coverage

artios header image

Benchtop Bios Podcast featuring CFO, Abid Ansari

21 September 2022 | Media coverage

Article-2-400×400

Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer

10 August 2022 | Press release

1 2 3 … 6 Next »

© Artios Pharma 2023 | Website by Granite 5

Terms & conditions | Privacy policy | Site map